ABSTRACT
INTRODUCTION
Preterm prelabuor rupture of fetal membrane (PPROM) defined as rupture of fetal membranes prior to the onset of labour at less than 37 weeks of gestation. Premature rupture of the membranes (PROM) complicates 10% of all gestations 1 and 2-4% of preterm pregnancy. 2 In India incidence of PROM varies between 7-12%. 3 it is an important controversial dilemma for obstetricians. Extensive research has done for PROM; still the rate of preterm birth has increased by 38% since 1981. 4 Risk factors of PROM are infections, genetic factors, zinc and vitamin C deficiency, smoking, trauma, amniocentesis, DOI: 10.18535/ijmsci/v2i12.09 ante partum bleeding, lower socio-economic status, cervical incompetence, sexual contact, polyhydramnios, etc.
PROM may result to chorioamnionitis, endomyometritis, increased caesarean rate, dysfunctional labour, PPH or septic shock in mother. It may causes respiratory distress syndrome (RDS), hyperbilirubinemia, hypothermia, intraventricular haemorrhage (IVH) and necrotizing enterocolitis, fetal distress, infections, septicemia, pneumonia or urinary tract infection. Late squeals are blindness, cerebral palsy, fetal deformation syndrome or Fetal pulmonary hypoplasia (incidence of it varies 3% to 28%. 5 PPROM can be diagnosed by history, clinical examination, pH, heat test, arborization (fern test), detection of placental alpha microglobulin-1 (amnisure test) , fetal fibronectin & -fetoprotein detection and ultrasound .The goal of management in PPROM is prolongation of pregnancy, the most commonly accepted management is expectant management (antibiotics, tocolytics,corticosteroids).
Efforts should do to prolong pregnancy by drugs such as chorioamniotic membrane sealing drug (Amnioseal). At the same time, early identification of infection is must and appropriate intervention should be done. Amnioseal acts by making Coordination between matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases. It is a gelatin capsule combination of proapoptolic bax gene p-53 inhibitor, myristoleate with antimicrobial peptides, and cytokine, IL-10 to target the immunological system. There are only few available studies with chorioamnitic sealing drugs, but showed better results than conventional management with antibiotics. This improved perinatal outcome with Amnioseal has prompted us to study this drug in PPROM. Obstetric and gynecological history had taken. Duration and amount of leaking had noted. Personal history, past history and family history had noted. Thorough and detailed examination of the patient carried out. Leaking per vaginum was confirmed by fern test. Routine investigations and ultrasonography had done. All the patients had explained about the study and drug. A prior consent was taken and then the patients were selected by randomization (alternate method). Inclusion crieteria was-ANC patients at GA 24-36 weeks with leaking per vagimum. Excluded were ANC patients with frank LPV and with active labour pain or having medical disorders. Patients were divided in 2 groups.
METHODS

210
Group A (24-30 wks) -Who were prescribed Aminoseal (Cases A1) and who were not prescribed the drug (Controls A2).
Group B (31-36 wks) -Who were prescribed Aminoseal (Cases B1) and who were not prescribed the drug (Controls B2).
All the patients were put on rest, antibiotics, prophylactic corticosteroids and tocolytics (Nifedipine) after sending a high vaginal swab for culture sensitivity. In addition to above, the cases in Group-A1 and B1 were prescribed capsule Amnioseal in following dosage schedule: -2 Capsules-Stat, 2 Capsules-After 3 hrs f/b 2Capsules-8 hrly till next 72 hrs then 1 Capsule BD x 15 days and then1 Capsule OD x 15 days.
Monitoring of pulse, temperature, fetal heart rate and fetal movement count was done every day. Contractions and tenderness of uterus was noted 12 hourly. Vaginal discharge examined daily. Weekly ultrasound for amniotic fluid index was done. CBC & CRP had done Every 48 hrly. Fortnightly liver function tests had done. The perinatal outcome was documented.
RESULTS
In our study (87.62%) maximum women were in age group 18-27 years and 65.33% patients were from rural area . 83.66% women were Hindus, 60.39% were booked patients and 61.38% were literate, 45.54% were of lower socioeconomic status and 50% of middle status, and 54.45% were primigravidas. The recurrence rate of PPROM was 58 (28.71%) and 30.69% were delivered by caesarean section (in this study). Out of 202 patients of PPROM, 93 (46.03%) cases (of Group-A1 and Group-A2) v/s 70 (30.65%) controls (of Group-B1 and Group-B2) had stoppage of demonstrable LPV after 24 hrs of treatment (Conventional and Amnioseal). Overall incidence of chorioamnionitis was 3.80% in 210 patients, whereas it was 1.94% in cases and 6.06% in control. 
CONCLUSION
Amnioseal is a novel drug with initial promising results, it helped in sealing the membrane and stoppage of leaking in 90.29% patients with PPROM treated with Amnioseal (Group-A1, A2), thus helped in prolongation of pregnancy, prevention of infection, thereby improving maternal and Neonatal outcomes .But this is a small study.
More studies and randomized controlled trials are required to see the efficacy of Amnioseal. Therefore, Amnioseal can be bringing to broader use in improving neonatal outcome in PPROM cases. Table- 
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